IE 11 is a very old Browser and it`s not supported on this site

Get an in-depth insight of
one of the leading biotech investors

SHAREHOLDER LETTER

Strategic reallocation of portfolio assets progressing

In the third quarter of 2024, stock markets remained volatile. The recent rate cut by the US central bank has improved the market dynamics for the biotechnology sector because lower interest rates typically increase the flow of investment capital into growth sectors such as biotech. BB Biotech AG shares showed a return of –9.2.% in CHF and –6.7% in EUR for the third quarter of 2024. The portfolio’s total return during this period was –6.6% in CHF, –4.4% in EUR, and –0.6% in USD. BB Biotech closed the third quarter with a net loss of CHF 157 mn. At the nine-month mark, BB Biotech showed a net profit of CHF 16 mn compared to a net loss of CHF 316 mn in the first nine months of 2023. Gains on the sale of several portfolio investments enabled new investments in faster-growing companies with promising drugs and pipeline assets.

Performance

BB BIOTECH (SIX)

CHF 36.40

30.09.2024

Share Price Performance YTD

–11.1%

Market capitalisation

CHF 2.0 bn

Net Asset Value (NAV)

CHF 40.65

BB BIOTECH (XETRA)

EUR 38.80

30.09.2024

Share Price Performance YTD

–11.0%

Market capitalisation

EUR 2.1 bn

Net Asset Value (NAV)

EUR 43.20

Portfolio

Argenx SE

11.5%

30.09.2024

Ionis Pharmaceuticals

10.6%

30.09.2024

Vertex Pharmaceuticals

8.0%

30.09.2024

Revolution Medicines

7.4%

30.09.2024

Alnylam Pharmaceuticals

7.4%

30.09.2024

Neurocrine Biosciences

7.2%

30.09.2024

Intra-Cellular Therapies

6.1%

30.09.2024

Agios Pharmaceuticals

5.6%

30.09.2024

prev
next